Core Viewpoint - A class action lawsuit has been filed against Fiserv, Inc. on behalf of investors who purchased shares during the specified class period, alleging misleading statements regarding the company's guidance and performance [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Fiserv revised its 2025 guidance in July 2025, indicating that while some initiatives were delayed, they were fundamentally sound [3]. - On October 29, 2025, Fiserv admitted that its July guidance was based on assumptions that were difficult to achieve, leading to a significant drop in share value [3]. - Following the acknowledgment of these misleading statements, Fiserv's shares fell by 44% in one day, from $126.17 on October 28, 2025, to $70.60 on October 29, 2025 [3]. Group 2: Investor Information - Investors who purchased Fiserv securities during the class period have until January 5, 2026, to seek appointment as lead plaintiff representatives [2]. - The law firm Berger Montague is handling the case and provides contact information for interested investors [4]. Group 3: Company Background - Fiserv is a global payments and financial technology company headquartered in Milwaukee, Wisconsin [2]. - Berger Montague, the law firm involved, is recognized for its expertise in complex civil litigation and has recovered over $50 billion for clients over its 55-year history [4].

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of SNDL Inc. regarding potential securities fraud or unlawful business practices by the company and its officers/directors [1] - On December 15, 2025, SNDL announced an amendment to its agreement to acquire 32 cannabis retail stores from 1CM, maintaining a total purchase price of $32.2 million in cash, but splitting the acquisition into two closings for regulatory approval [2] - Following the announcement of the amended acquisition agreement, SNDL's stock price fell by $0.29 per share, or 13.12%, closing at $1.92 per share on December 15, 2025 [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers or directors [1] Group 1: Company Developments - Galectin Therapeutics announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [2] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating ongoing communication between the company and the agency [2] - Galectin plans to pursue a follow-up Type C meeting with the FDA to finalize the remaining components of its next clinical trial design, although key aspects of the trial design remain unresolved [2] Group 2: Market Reaction - Following the announcement regarding the FDA's response, Galectin's stock price fell by $1.78 per share, representing a 28.9% decrease, closing at $4.38 per share on December 19, 2025 [3]

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Firefly Aerospace Inc. (NASDAQ: FLY) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its business operations and growth prospects [1][4]. Group 1: Class Action Details - The class action is for individuals and entities that purchased Firefly common stock during the initial public offering on August 7, 2025, and between August 7, 2025, and September 29, 2025 [3]. - Shareholders are encouraged to register for the class action by January 12, 2026, to potentially be appointed as lead plaintiffs, although this is not required to participate in any recovery [5]. Group 2: Allegations Against Firefly Aerospace - The complaint alleges that Firefly overstated the demand and growth prospects for its Spacecraft Solutions offerings [4]. - It is claimed that Firefly also overstated the operational readiness and commercial viability of its Alpha rocket program [4]. - The lawsuit suggests that these misrepresentations would likely have a material negative impact on the company once revealed [4]. Group 3: Law Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit and illegal business practices [6]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements that led to artificial inflation of stock prices [6].

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. and its senior executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Eastern District of Virginia, titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019, and investors have until January 12, 2026, to seek lead plaintiff status [3]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Stride securities [3]. Group 2: Allegations Against Stride - Stride, an education technology company, is accused of inflating enrollment numbers by retaining "ghost students," neglecting compliance requirements, and providing a poor customer experience, leading to higher withdrawal rates and lower conversion rates [4]. - The company claimed to be experiencing growth and strong demand, which is now alleged to be misleading [4]. Group 3: Stock Performance Impact - On September 14, 2025, a report of the lawsuit caused Stride's stock to drop by $18.60 per share, over 11%, from $158.36 to $139.76 [5]. - Following an admission of poor customer experience on October 28, 2025, Stride's stock plummeted by $83.48 per share, more than 54%, from $153.53 to $70.05, with an estimated impact of 10,000-15,000 fewer enrollments [6].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Central District of California, captioned Hern v. Alexandria Real Estate Equities, Inc., et al., No. 2:25-cv-11319 [3]. - Investors have until January 26, 2026, to request to be appointed to lead the case [3]. - The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Alexandria Real Estate securities [3]. Group 2: Company Performance and Stock Impact - Alexandria Real Estate, a real estate investment trust focused on life science industries, reported lower occupancy rates and slower leasing activity, leading to a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property [4][5]. - On October 27, 2025, the company announced disappointing results for Q3 2025 and reduced guidance for the fiscal year, causing its stock price to drop by $14.93 per share, or over 19%, from $77.87 to $62.94 [6].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and its senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to customers having excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire disclosed that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - The stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025, following this announcement [8].

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visiting: https://w ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Outset Medical and its officers/directors, following disappointing financial results and a significant drop in stock price [1][3]. Financial Performance - On November 10, 2025, Outset Medical reported non-GAAP earnings per share of -$0.69, missing consensus estimates by $0.03 [3]. - The company generated revenue of $29.43 million for the third quarter of 2025, which was $1.27 million below consensus estimates [3]. - Outset Medical revised its 2025 revenue outlook to a range of $115 million to $120 million, down from a previous range of $122 million to $126 million, citing delays in closing large opportunities [3]. Stock Market Reaction - Following the announcement of the financial results, Outset Medical's stock price fell by $5.85 per share, or 48.47%, closing at $6.22 per share on November 11, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Live Oak Bancshares, Inc. and its officers or directors, following the company's announcement of material misclassifications in its financial statements [1][3]. Group 1: Company Financials - On November 12, 2025, Live Oak disclosed that it would amend its 2024 Annual Report and Quarterly Reports for the periods ended March 31, 2025, and June 30, 2025, to restate its Consolidated Financial Statements due to errors in cash flow classifications [3]. - The company identified a material misclassification related to cash flows from the sale of loan participations, which led to a conclusion that a material weakness exists in its internal control over financial reporting [3]. - Following this announcement, Live Oak's stock price decreased by $0.80 per share, or 2.49%, closing at $31.29 per share on November 13, 2025 [3]. Group 2: Legal Investigation - Pomerantz LLP is actively seeking claims from investors of Live Oak Bancshares, indicating a potential class action lawsuit due to the alleged securities fraud [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation and potential participation in the class action [1][2]. Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a legacy of recovering significant damages for class members over its 85-year history [4].